Peginterferon alfa with ribavirin is recommended as a possible treatment for children and young people with chronic hepatitis C.
What does this mean?
If your (or your child's) doctor thinks that peginterferon alfa with ribavirin is the right treatment, you (or your child) should be able to have the treatment on the NHS.
Peginterferon alfa with ribavirin should be available on the NHS within 3 months of the guidance being issued.
This guidance partially updates NICE technology appraisal guidance 106 peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C and NICE technology appraisal guidance 75 interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.